scispace - formally typeset
G

Gordon Broderick

Researcher at Rochester General Health System

Publications -  97
Citations -  3548

Gordon Broderick is an academic researcher from Rochester General Health System. The author has contributed to research in topics: Chronic fatigue syndrome & Immune system. The author has an hindex of 31, co-authored 93 publications receiving 3130 citations. Previous affiliations of Gordon Broderick include Southeastern University & University of Rochester.

Papers
More filters
Journal ArticleDOI

Coarse-grained molecular simulation of diffusion and reaction kinetics in a crowded virtual cytoplasm.

TL;DR: The simulated effect of crowding on barnase-barstar dimerization, an experimentally characterized example of a bimolecular association reaction, reveals a biphasic time course, indicating that crowding exerts different effects over different timescales, and illustrates that quantitative realism in biosimulation will depend to some extent on mesoscale phenomena that are not currently well understood.
Journal ArticleDOI

Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets.

TL;DR: Many transcriptome changes previously described in rejection are features of a large‐scale disturbance characteristic of rejection but occurring at lower levels in many forms of injury, indicating that transcriptome disturbances in renal transplants have a stereotyped internal structure.
Journal ArticleDOI

A formal analysis of cytokine networks in chronic fatigue syndrome.

TL;DR: Network analysis to the co-expression of 16 cytokines in CFS subjects and healthy controls identifies key sub-networks such as IL-2:IFN-γ:TNF-α that might be targeted in restoring normal immune function.
Journal ArticleDOI

Biomarkers for chronic fatigue

TL;DR: It is proposed that new insight will depend on the ability to develop and deploy an integrative profiling of CFS/ME pathogenesis at the molecular level, and until such a molecular signature is obtained efforts to develop effective treatments will continue to be severely limited.